The substantial heterogeneity and hierarchical organization in liver cancer support the theory of liver cancer stem cells (LCSCs). However, the relationship between chronic hepatic inflammation and LCSC generation remains obscure. Here, we observed a close correlation between aggravated inflammation and liver progenitor cell (LPC) propagation in the cirrhotic liver of rats exposed to diethylnitrosamine. LPCs isolated from the rat cirrhotic liver initiated subcutaneous liver cancers in nonobese diabetic/severe combined immunodeficient mice, suggesting the malignant transformation of LPCs toward LCSCs. Interestingly, depletion of Kupffer cells in vivo attenuated the LCSC properties of transformed LPCs and suppressed cytokeratin 19/Oval cell 6-positive tumor occurrence. Conversely, LPCs cocultured with macrophages exhibited enhanced LCSC properties. We further demonstrated that macrophage-secreted tumor necrosis factor-a triggered chromosomal instability in LPCs through the deregulation of ubiquitin D and checkpoint kinase 2 and enhanced the self-renewal of LPCs through the tumor necrosis factor receptor 1/Src/signal transducer and activator of transcription 3 pathway, which synergistically contributed to the conversion of LPCs to LCSCs. Clinical investigation revealed that cytokeratin 19/Oval cell 6-positive liver cancer patients displayed a worse prognosis and exhibited superior response to sorafenib treatment. Conclusion: Our results not only clarify the cellular and molecular mechanisms underlying the inflammation-mediated LCSC generation but also provide a molecular classification for the individualized treatment of liver cancer. (HEPATOLOGY 2017;66:1934-1951. P rimary liver cancer (PLC) is the sixth most prevalent malignancy and the second leading cause of cancer-related death in men.
The substantial heterogeneity and hierarchical organization in liver cancer support the theory of liver cancer stem cells (LCSCs). However, the relationship between chronic hepatic inflammation and LCSC generation remains obscure. Here, we observed a close correlation between aggravated inflammation and liver progenitor cell (LPC) propagation in the cirrhotic liver of rats exposed to diethylnitrosamine. LPCs isolated from the rat cirrhotic liver initiated subcutaneous liver cancers in nonobese diabetic/severe combined immunodeficient mice, suggesting the malignant transformation of LPCs toward LCSCs. Interestingly, depletion of Kupffer cells in vivo attenuated the LCSC properties of transformed LPCs and suppressed cytokeratin 19/Oval cell 6-positive tumor occurrence. Conversely, LPCs cocultured with macrophages exhibited enhanced LCSC properties. We further demonstrated that macrophage-secreted tumor necrosis factor-a triggered chromosomal instability in LPCs through the deregulation of ubiquitin D and checkpoint kinase 2 and enhanced the self-renewal of LPCs through the tumor necrosis factor receptor 1/Src/signal transducer and activator of transcription 3 pathway, which synergistically contributed to the conversion of LPCs to LCSCs. Clinical investigation revealed that cytokeratin 19/Oval cell 6-positive liver cancer patients displayed a worse prognosis and exhibited superior response to sorafenib treatment. Conclusion: Our results not only clarify the cellular and molecular mechanisms underlying the inflammation-mediated LCSC generation but also provide a molecular classification for the individualized treatment of liver cancer. (HEPATOLOGY 2017; 66:1934 -1951 ). P rimary liver cancer (PLC) is the sixth most prevalent malignancy and the second leading cause of cancer-related death in men. (1) Increasing evidence has indicated that the occurrence of liver cancer is attributed to the propagation of liver cancer stem cells (LCSCs). (2) LCSCs possess unlimited self-renewal capacity and are critical in the initiation, progression, chemoresistance, and postsurgical recurrence of PLC. (3) Nevertheless, the molecular genetics and clinical significance of LCSCs remain unclear.
In comparison with stem cells, progenitor cells in adult organs exhibit limited self-renewal capability and reduced differentiation potential. Liver progenitor cells Abbreviations: AFP, alpha-fetoprotein; CD, cluster of differentiation; ChIP, chromatin immunoprecipitation; Chk2, checkpoint kinase 2; CIN, chromosomal instability; CK19, cytokeratin 19; CM, conditioned medium; DEN, diethylnitrosamine; HCC, hepatocellular carcinoma; IgG, immunoglobulin G; IL-6, interleukin-6; LCSC, liver cancer stem cell; LEPC, liver epithelial progenitor cell; LPC, liver progenitor cell; LPS, lipopolysaccharide; NOD/ SCID, nonobese diabetic/severe combined immunodeficient; OV6, Oval cell 6; PLC, primary liver cancer; STAT3, signal transducer and activator of transcription 3; TNF-a, tumor necrosis factor-a; TNFR, TNF receptor; UBD, ubiquitin D.
(LPCs), also termed oval cells in rodents, are small normal epithelial cells located in the canals of Hering, (4) which can be distinguished by specific cell surface markers such as Oval cell 6 (OV6) and cytokeratin 19 (CK19). (5, 6) LPC activation was reported to be associated with tissue damage and inflammation, (7) but the compensatory expansion of LPCs only occurred in cases where hepatocyte regeneration is largely restricted to the liver with severe chronic injury. A recent study showed that reactivation of the generative capacity in adult LPCs markedly increased their susceptibility to transformation, which provides direct evidence that cell generative capacity can be a major determinant of organ cancer risk. (8) Nevertheless, whether LPCs are involved in LCSC generation during inflammationelicited hepatocarcinogenesis deserves exploration.
Chronic nonresolving inflammation is considered a distinctive feature and causal factor of hepatocarcinogenesis. However, the cellular and molecular machinery linking chronic inflammation to tumorigenesis remains unclear. Kupffer cells, the resident macrophages in hepatic tissue, are the largest population of innate immune cells in the liver. (9) Tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6) are the most essential proinflammatory cytokines secreted by Kupffer cells in the liver. Hepatocytespecific Ij-B transgenic or IL-6 knockout mice developed fewer tumors upon chronic liver inflammation or diethylnitrosamine (DEN) exposure, suggesting important roles of TNF-a and IL-6 in hepatocyte transformation. (10, 11) However, the roles of TNF-a and IL-6 in LPC transformation and LCSC generation remain largely unknown. In this study, we investigated the molecular mechanism of chronic inflammation-triggered conversion of LPCs into LCSCs and delineated the clinical significance of LPC-derived PLCs.
Materials and Methods

PATIENTS AND CLINICAL SAMPLES
Fibrotic liver samples of patients were obtained from Eastern Hepatobiliary Surgery Hospital (Shanghai, China). Cirrhosis was defined by pathological features of extensive fibrosis, distortion of the hepatic architecture, and formation of regenerative nodules. In total, 163 patients (cohort 1), consisting of 66 patients with CK19
1 and OV6 1 liver cancer tissues and 97 patients with CK19 2 or OV6 2 liver cancer, were included, who underwent surgical resection at Eastern Hepatobiliary Surgery Hospital (Shanghai, China). Detailed clinical pathological characteristics of the patients are listed in Supporting Table S1 . In cohort 2, a total of 280 liver cancer patients who underwent curative resection followed by sorafenib treatment (n 5 203) or not (n 5 77) at Eastern Hepatobiliary Surgery Hospital from December 2008 to June 2015 were included. The characteristics of patients are described in Supporting Table S3 . Sorafenib was given to patients at a dose of 400 mg twice a day. Treatment interruptions and up to two dose reductions (200 mg twice a day and 200 mg once a day) were permitted for drug-related adverse effects. Immunohistochemical analysis of tumor sections was performed as described. (12) The primary antibodies used are listed in Supporting Table S4 . Microscopic evaluation was performed by a pathologist, blinded to the clinical data. Time to recurrence was defined as the interval between the dates of surgery and recurrence; if recurrence was not diagnosed, then the patients were censored on the date of death or the last follow-up. All of the above studies were approved by the ethics committee of the Eastern Hepatobiliary Surgery Hospital.
ARTICLE INFORMATION:
DEN1CCl 4 -INDUCED MOUSE LIVER CANCER MODEL
SOX9-Cre
ERT2 DTR-eGFP mice were generated by crossing SOX9-Cre ERT2 mice with pCAG-loxp-stoploxp-DTR-2A-eGFP mice. The DEN1CCl 4 -induced liver cancer model was established as described. (13) In brief, 15-day-old SOX9-Cre ERT2 DTR-eGFP mice were injected with DEN (25 mg/kg intraperitoneally), followed by weekly injections of CCl 4 (5 mL/kg intraperitoneally, 10% dissolved in olive oil) for 4 months.
DEN-INDUCED RAT CARCINOGENESIS
Male Wistar rats were injected intraperitoneally with DEN (Sigma-Aldrich, St. Louis, MO) at 70 mg/kg body weight once a week for 10 weeks. Ultrasonic imaging was performed to monitor liver cancer development. Two rats were sacrificed every 2 weeks, and the remaining rats were sacrificed 24 weeks after DEN administration. Five agematched normal rats were used as normal controls.
DEPLETION OF KUPFFER CELLS IN VIVO
Gadolinium chloride hexahydrate (GdCl 3 Á6H 2 O; Sigma-Aldrich) in sterile isotonic saline was administered intravenously through the tail vein at a dose of 10 mg/kg body weight twice per week without anesthesia. Control rats were injected with identical volumes of normal saline intravenously twice weekly.
MAGNETIC-ACTIVATED CELL SORTING OF OV6
1 LPCs
The livers of Wistar rats were perfused and digested using a two-step perfusion protocol, and liver nonparenchymal cells were collected as described. (14) For magnetic-activated cell sorting purification, liver nonparenchymal cells were labeled with anti-OV6 antibodies (R&D Systems, Minneapolis, MN) and incubated with antimouse immunoglobulin G (IgG) beads (Miltenyi Biotec, Auburn, CA). OV6 1 cells were collected through positive selection for further experiments.
LPC LINES AND CHEMICAL INHIBITORS
The rat LPC-like cell line WB-F344 (15, 16) and murine liver epithelial progenitor cells (LEPCs) (17) were cultured in Dulbecco's modified Eagle's medium (Invitrogen Corporation, Carlsbad, CA) supplemented with 0.5% and 5% fetal bovine serum (Gibco, Invitrogen), respectively. For long-term treatment, WB-F344 cells and LEPCs were treated with TNF-a or IL-6 (Peprotech, Rocky Hill, NJ) at 1 ng/mL for 20 weeks. The cells were then named as WB-TNF or WB-IL-6 and LEPC-TNF or LEPC-IL-6, respectively. The chemical signal transducer and activator of transcription 3 (STAT3) inhibitor S3I-201 and the Src inhibitor dasatinib were purchased from Selleck Chemicals.
SPHEROID ASSAY
WB-F344 cells or LEPCs that underwent longterm TNF-a treatment were plated in six-well ultralow attachment culture dishes at 3 3 10 4 cells/well. The number of spheroids was counted 1 week after seeding, and representative images were acquired.
ANCHOR-INDEPENDENT GROWTH ASSAY
In total, 1.5 3 10 4 WB-F344 cells or LEPCs/mL that underwent long-term TNF-a treatment were suspended in Dulbecco's modified Eagle's medium, mixed with Matrigel Basement Membrane Matrix (BD Bioscience, Bedford, MA) at a ratio of 2:1 to a final volume of 150 lL, and then cultured in 96-well plates for 1 week. Colonies that formed within the gel were counted using a microscope, and representative images were acquired.
XENOGRAFT TUMOR FORMATION
WB-CON, WB-TNF, or WB-IL6 cells were mixed with Matrigel at a ratio of 1:1 and then inoculated subcutaneously into the flanks of nonobese diabetic/severe combined immunodeficient (NOD/ SCID) mice at 6 3 10 6 cells/mouse. Mice were sacrificed at week 10 postinoculation, and tumor incidence was assessed as described.
IMMUNOFLUORESCENCE STAINING
Frozen sections of fresh human and rat liver samples were incubated with anti-CK19 antibody and mouse anti-OV6 antibody (R&D Systems), followed by incubation with Alexa Fluor 488-conjugated antimouse IgG and Alexa Fluor 555-conjugated antirabbit IgG (Invitrogen). Nuclear staining of tissue samples was conducted using 4,6-diamidino-2-phenylindole. Representative images were acquired using an Olympus IX70 microscope.
TRANSIENT TRANSFECTION OF SMALL INTERFERING RNA
WB-F344 cells or LEPCs were seeded into a sixwell plate until they reached 80%-90% confluence. Transfection of si-Src or its negative control was performed in each well in the absence of serum with small interfering RNA transfection reagent according to the manufacturer's instructions (Polyplus, Illkirch, France). The sequence of si-Src is as follows: sense, 5 0 -GGCUGAGGAGUGGUACUUUTT-3 0 and antisense, 5
0 -AAAGUACCACUCCUCAGCCTT-3 0 .
REAL-TIME PCR AND IMMUNOBLOT ANALYSIS
The transcripts of specific genes were measured by real-time PCR using a ViiA 7 Dx Real-Time PCR System (Applied Biosystems). The sequences of the primers used are listed in Supporting Table S5 . Cell lysate extracts were analyzed by immunoblot using primary antibodies listed in Supporting Table S4 and IRDye 800CW-conjugated secondary antibody (LI-COR Biosciences).
CHROMATIN IMMUNOPRECIPITATION ASSAY
A chromatin immunoprecipitation (ChIP) assay was performed using a Magna ChIP HiSens Kit (Millipore Corp., Bedford, MA) according to the manufacturer's instructions. Chromatin was immunoprecipitated with STAT3 antibody. The sequences of the primers are listed in Supporting Table S6 .
FLOW-CYTOMETRIC ANALYSIS
Hepatoma cells were incubated with the primary antibody rabbit anti-epithelial cell adhesion molecule and then with the secondary antibody fluorescein isothiocyanate-conjugated antirabbit IgG or with phycoerythrin-conjugated antirat cluster of differentiation 90 (CD90) alone. Flow-cytometric analysis was performed using a MoFlo XDP from Beckman Coulter according to the manufacturer's instructions.
KARYOTYPING
Cells were treated with 0.2 lg/mL colchicine (Sigma-Aldrich) to induce metaphase arrest. After the cells were trypsinized, they were resuspended in 0.075 M KCl and then fixed with Carnoy's fixative (3:1 methanol:glacial acetic acid). Cells were collected by centrifugation and then resuspended in fixative. The cell suspension was dropped onto glass slides, airdried, and then stained with 4,6-diamidino-2-phenylindole. Metaphase spreads were imaged by confocal microscopy (Leica).
DATA ANALYSIS
Differences between variables were assessed using two-tailed Student t tests. The data are expressed as the mean 6 SD. Kaplan-Meier and log-rank analysis were performed to compare patient survival between subgroups. Pearson's correlation analysis was conducted to assess the correlation statistics between two variables. P < 0.05 was considered statistically significant.
Results
TRANSFORMATION OF EXPANDED LPCs GIVES RISE TO LCSCs UPON CHRONIC INFLAMMATION
To explore the contribution of chronic inflammation in the conversion of LPCs to LCSCs, LPC lineage tracing mice (SOX9-Cre ERT2 DTR-eGFP) were treated with the combination of DEN and CCl 4 . Disappointingly, mouse livers did not exhibit typical cirrhosis like patients before tumor formation, and the LPC propagation was limited (Supporting Fig. S1A ). We then used a DEN-induced rat hepatocarcinogenesis model, which presents typical hepatitis (1-10w), fibrosis and cirrhosis (11-18w), and liver cancer (19-22w) , better resembling the pathogenesis of human liver cancer (Supporting Fig. S1B ). In parallel, OV6-positive LPCs were slightly increased in early stages of hepatocarcinogenesis but significantly expanded at the stage of cirrhosis, which is quite similar to what occurs in human liver cancer development (Fig. 1A) . The livers of DEN-administered rats displayed evident Kupffer cell (CD68 1 ) infiltration and inflammatory cytokine production, particularly at the portal regions (Fig. 1B) . Interestingly, expression of LCSC markers was notably enhanced during the process of To further confirm the tumor initiating ability of LPCs exposed to chronic inflammation, we isolated the expanded LPCs from the cirrhotic liver of rat. OV6 expression was limited in the expanded LPCs in interlobular septum of the cirrhotic liver, while in the intralobular area OV6 expression was hardly detected (Fig. 1E) . Moreover, isolated OV6
1 LPCs were much smaller than hepatocytes (Supporting Fig. S1E ), and the gene expression pattern was dramatically distinct from that of hepatocytes (Supporting Fig. S1F ). Isolated LPCs were subcutaneously inoculated into NOD/SCID mice to evaluate their tumorigenicity. LPCs from DEN-treated rats formed tumors (2/5) 6 weeks later, while LPCs from control rats produced no tumor (Fig. 1F) . As expected, expression of alphafetoprotein (AFP) and CK19 was detected in these LPC-derived tumors, and CD133
1 or CD24 LCSCs were also observed (Supporting Fig. S1G ). These data suggest that the expanded LPCs could be converted to LCSCs during chronic inflammation.
MACROPHAGE INFILTRATION FACILITATES CONVERSION OF LPCs INTO LCSCs
Kupffer cells are the primary source of hepatic inflammatory cytokines. (18) To explore the influence of Kupffer cells on LPC transformation, we depleted Kupffer cells by intravenous injection of GdCl 3 (19) during DEN-induced rat hepatocarcinogenesis ( Fig.  2A; Supporting Fig. S2A ). The depletion of Kupffer cells resulted in a dramatic reduction in LCSC markers in isolated LPCs ( Fig. 2A) . Furthermore, stemnessassociated gene expression and self-renewal capacity were strikingly attenuated in isolated LPCs upon the depletion of Kupffer cells (Fig. 2B) . Consistently, tumor formation in livers of DEN-administered rats was dramatically suppressed, and no OV6 1 or CK19 1 tumor was observed, implying that LPC conversion to LCSCs was abrogated upon Kupffer cell depletion (Fig. 2C,D) . To further confirm the essential role of macrophages in LPC transformation, the rat LPC-like cell line WB-F344 was used for in vitro verification. We found that WB-F344 cells cocultured with lipopolysaccharide (LPS)-activated rat macrophages exhibited enhanced self-renewal ability (Fig. 2E) . Moreover, WB-F344 cells cultured in 30% conditioned medium (CM) from LPS-activated macrophages displayed elevated LCSC marker expression and enhanced anchor-independent growth ability, supporting a positive role of macrophages in the malignant transformation of LPCs to LCSCs ( Fig. 2F ; Supporting Fig. S2B ).
TNF-a, BUT NOT IL-6, PROMOTES MALIGNANT TRANSFORMATION AND EXPANSION OF LPCs
Considering that TNF-a and IL-6 are major inflammatory cytokines produced by Kupffer cells, we explored whether TNF-a or IL-6 was responsible for the malignant transformation of LPCs to LCSCs. WB-F344 cells subjected to long-term treatment with low dosage of TNF-a, but not IL-6, exhibited potent tumorigenicity in NOD/SCID mice (Fig. 3A,B) . Aberrant expression of AFP, CK19, and OV6 was detected in WB-TNF tumors (Fig. 3C) . Intriguingly, despite the high levels of TNF receptor (TNFR) in LPC, expression of IL-6 receptor b (gp130), an indispensable subunit for IL-6 receptor, was extremely low and even undetectable in LPCs, which explained why IL-6 did not trigger the malignant transformation of 1 LPCs were isolated from livers of DEN-treated rats at week 15 by magnetic-activated cell sorting. Sorted OV6
1 LPCs (5 3 10 5 ) were inoculated subcutaneously into NOD/SCID mice. Xenografted tumors were excised and subjected to hematoxylin and eosin, immunohistochemical, and immunofluorescence staining at week 6 postinoculation. Scale bar, 100 lm. Abbreviations: EpCAM, epithelial cell adhesion molecule; H&E, hematoxylin and eosin; MACS, magnetic-activated cell sorting; s.c., subcutaneous.
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LPCs (Supporting Fig. S3A ). Consistently, WB-TNF and LEPC-TNF cells displayed an enhanced anchorindependent growth capacity compared with control cells (Supporting Fig. S3B,C) . Flow-cytometric analysis revealed that long-term TNF-a exposure led to a notable increase in the proportion of CD90 1 or epithelial cell adhesion molecule-positive cells ( Fig. 3D;  Supporting Fig. S3D ). Moreover, both WB-TNF and LEPC-TNF cells presented augmented spheroid formation, suggesting that TNF-a exposure reinforced the self-renewal ability of LPCs (Supporting Fig.  S3E ). The in vitro and in vivo limiting dilution assay of WB-TNF and LEPC-TNF cells further supported the conversion of LPCs to LCSCs after long-term TNFa treatment ( Fig. 3E; Supporting Fig. S3F ). As expected, neutralization of TNF-a compromised the macrophage CM-enhanced self-renewal of WB-F344 cells (Fig. 3F ). These data imply that macrophagederived TNF-a triggers the transformation of LPCs to LCSCs.
TNF-a EXPOSURE TRIGGERS CHROMOSOMAL INSTABILITY IN LPCs
TNF-a exerts a tumor initiating role by inducing cytogenetic changes including DNA damage and chromosomal instability (CIN). (20, 21) Expression of the DNA damage indicator c-H2AX was marginally changed, excluding the possibility of DNA damageelicited cytogenetic alterations in LPCs upon TNF-a exposure (Supporting Fig. S4A) . However, karyotype analysis demonstrated striking aneuploidy in chronically TNF-a-treated LPCs, suggesting that chronic TNF-a exposure in LPCs causes CIN (Fig. 4A,B;  Supporting Fig. S4B ). Consistently, long-term macrophage CM-treated LPCs exhibited elevated aneuploidy, which could be blocked by TNFR1 interference ( Fig. 4C; Supporting Fig. S4C ). One possible mechanism underlying CIN is centrosomemediated asymmetric chromosome segregation. (22) However, we found that <6% of WB-TNF cells possessed numerical or structural centrosomal aberrations, which excluded the possibility of centrosomal abnormalities in TNF-a-triggered CIN in LPCs (Supporting Fig. S4D ). Expression of key CIN mediators was then examined in long-term TNF-a-treated LPCs. Aberrant expression of ubiquitin D (UBD) and checkpoint kinase 2 (Chk2) was detected in TNF-a-treated LPCs or LPCs treated with macrophage CM, and it could be completely blocked by TNFR1 interference, suggesting that TNF-a exposure triggered CIN in LPCs through deregulation of UBD and Chk2 ( Fig.  4D,E; Supporting Fig. S4E ).
TNF-a ENHANCES THE SELF-RENEWAL OF LPCs THROUGH ACTIVATING STAT3
Apart from genetic alteration, improving the selfrenewal ability of progenitor cells which possess limited self-renewal potential could also facilitate cancer stem cell (CSC) generation. (23) To disclose the molecular mechanism underlying the enhanced self-renewal ability of LPCs exposed to TNF-a, we examined the expression of key self-renewal regulators in TNF-atreated LPCs. The mRNA and protein levels of Nanog and Lin28 were significantly up-regulated in WB-TNF and LEPC-TNF cells ( Fig. 5A; Supporting  Fig. S5A,B) . Next, we examined the activation status of several stemness-associated pathways including mitogen-activated protein kinase, Akt/mammalian target of rapamycin, and Janus kinase/STAT3. (24, 25) Activation of STAT3, but not the other signaling molecules, was significantly increased in WB-TNF and LEPC-TNF cells (Fig. 5B,C; Supporting Fig. S5C ). Consistently, STAT3 activation was detected in propagated LPCs during DEN-triggered rat hepatocarcinogenesis (Supporting Fig. S5D ). STAT3 was reported to promote the transcription of Nanog and The phosphorylation status of STAT3, mammalian target of rapamycin, and extracellular signal-regulated kinase in WB-CON and WB-TNF cells was determined by western blot. (C) Cytoplasmic and nuclear extracts of WB-CON and WB-TNF cells were subjected to immunoblotting against phosphorylated STAT3 and p65. Glyceraldehyde 3-phosphate dehydrogenase and histone H3 were used as loading controls for cytoplasm and nucleus. (D) ChIP assay was performed in WB-CON and WB-TNF cells using STAT3 antibody. Real-time PCR analysis was performed using a specific primer for the promoter region of Lin28A, Lin28B, or Nanog. Normal mouse antibody served as a negative control. (E) The mRNA levels of Lin28 or Nanog in WB-CON and WB-TNF cells treated with S3I-201 (100 nM) were examined by real-time PCR analysis. (F) Spheroid formation assay of WB-CON and WB-TNF cells exposed to S3I-201 (100 nM). *P < 0.05. Abbreviations: CON, control; DMSO, dimethyl sulfoxide; ERK, extracellular signal-regulated kinase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; mTOR, mammalian target of rapamycin; p-ERK, phosphorylated ERK. Lin28 through binding to their promoters. (26, 27) By ChIP assay, enrichment of STAT3 on the promoter region of Lin28 and Nanog was significantly increased in WB-TNF cells compared with control cells (Fig.  5D) . Moreover, the specific STAT3 inhibitor S3I-201 dramatically attenuated the up-regulation of Lin28 and Nanog ( Fig. 5E; Supporting Fig. S5E ) and enhanced sphere-forming ability ( Fig. 5F; Supporting  Fig. S5F ) in WB-TNF and LEPC-TNF cells, indicating that long-term TNF-a treatment enhanced the self-renewal capacity of LPCs through STAT3 activation.
Src IS RESPONSIBLE FOR TNF-a-INDUCED STAT3 HYPERACTIVATION
To clarify how TNF-a regulates STAT3 activation, we determined the positive and negative regulators of STAT3. Nuclear factor-jB inhibitor showed no influence on the activation of STAT3 excluding its role in TNF-a-elicited STAT3 activation in LPCs (Supporting Fig. S6A ). Intriguingly, significant induction of Src phosphorylation was detected in LPCs exposed to TNF-a ( Fig. 6A; Supporting Fig. S6B ). To confirm the role of Src in TNF-a-induced STAT3 activation, WB-TNF cells were treated with dasatinib, a specific Src inhibitor or small interfering RNA specific to Src. STAT3 activation was notably suppressed concomitant with Src inhibition in WB-TNF cells ( Fig. 6B ; Supporting Fig. S6C,D) . Moreover, dasatinib treatment or si-Src transfection significantly compromised the upregulation of Lin28 and Nanog ( Fig. 6C; Supporting  Fig. S6E,F) and suppressed the self-renewal ability in WB-TNF and LEPC-TNF cells ( Fig. 6D ; Supporting Fig. S6G,H) . Consistently, activated Src and STAT3 were detected in the xenograft tumors of WB-TNF cells (Fig. 6E) . Collectively, we proposed that macrophage-secreted TNF-a not only triggered chromosomal instability in LPCs through the deregulation of UBD and Chk2 but also enhanced the self-renewal of LPCs through a TNFR1/Src/STAT3-dependent pathway, which synergistically contributed to LCSC generation (Fig. 6F ).
CK19
1
OV6
1 LIVER CANCERS DISPLAY AN AGGRESSIVE PHENOTYPE AND CORRELATE WITH POOR PROGNOSIS Expression of the biliary lineage/LPC marker CK19, which is routinely examined in our hospital, was detected in approximately 9% of 7,617 PLC patients who underwent resection at our hospital from 2007 to 2009. Nonetheless, OV6 expression was detected in up to 65% of CK19 1 tumors and was rarely detected in CK19 2 tumors (Fig. 7A,B) . We then assessed the clinical significance of CK19
1
OV6
1 liver cancer, which might originate from LPCs. Intriguingly, CK19
1
OV6
1 was associated with high AFP levels and local metastasis (Supporting Fig.  S7A ,B and Table S1 ). Kaplan-Meier survival analysis showed that CK19
1
OV6
1 patients exhibited earlier recurrence and shorter overall survival time (median overall survival times were 16 and 34.7 months, respectively) compared with the control patients (Fig. 7C,D) . In univariate and multivariate analyses, either high AFP levels, poor differentiation, or CK19 1
1 classification was an independent prognostic factor for patient disease-free survival time ( Fig. 7E ; Supporting Table S2 ). CK19
1
OV6
1 classification together with encapsulation, multiple tumor number, tumor size (>5 cm), and poor differentiation were all independent prognostic factors for patient overall survival time ( Fig. 7F ; Supporting Table S3 ). These data implied that CK19
1
OV6
1 tumors, at least partially, might have an LPC origin, and the combination of CK19 and OV6 could serve as a novel biomarker for liver cancer stratification.
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LIVER CANCERS EXHIBIT SUPERIOR RESPONSE TO SORAFENIB THERAPY
Sorafenib is the only targeted agent for liver cancer treatment and is known to inhibit STAT3 activation. (28, 29) Considering the aberrant activation of STAT3 in WB-TNF or LEPC-TNF cells, it is interesting to explore their responses to sorafenib treatment. As expected, STAT3 activation was dramatically abolished by sorafenib treatment in WB-TNF and LEPC-TNF cells (Fig. 8A) . Consistently, sorafenib treatment abrogated the up-regulation of Lin28 and Nanog ( Fig.  8B; Supporting Fig. S8A ) and suppressed the selfrenewal ability in WB-TNF and LEPC-TNF cells ( Fig. 8C; Supporting Fig. S8B ). It has been well accepted that STAT3 plays a prosurvival and antiapoptotic role in various cell types. Herein we found that WB-TNF and LEPC-TNF cells exhibited enhanced sensitivity upon sorafenib exposure but not cisplatin treatment ( Fig. 8D; Supporting Fig. S8C ), suggesting that LPC-derived liver cancer could be sensitive to sorafenib therapy. Moreover, our survival analysis revealed that the therapeutic effect of sorafenib for liver cancer was generally disappointing but that CK19 1 OV6 1 liver cancer patients exhibited superior overall survival after sorafenib treatment ( Fig. 8E,F;  Supporting Fig. S8D ), suggesting that patients with LPC-derived liver cancer could benefit from sorafenib administration.
Discussion
Accumulating evidence has suggested the existence of LCSCs, which are responsible for tumor formation and chemoresistance. Hepatocytes, hepatoblasts, and adult LPCs have been proposed to be cell origins of LCSCs (30) ; but these concepts remain controversial, and their clinical relevance is scarce. The cellular and molecular mechanisms underlying LCSC generation are far from fully understood. In this report, we provided evidence indicating that the transformation of expanded LPCs under an inflammatory microenvironment contributes to LCSC generation. We further clarified that macrophage-secreted TNF-a triggered CIN and enhanced self-renewal capacity in LPCs, which synergistically facilitated LCSC generation and expansion.
Chronic inflammation is a potent driving force in liver cancer development, (31) and understanding the underlying cellular and molecular mechanisms could improve the existing strategy for liver cancer prevention and treatment. Hepatocytes are known as the main cellular origin of liver cancer, while excessively expanded LPCs upon chronic liver injury are also potent candidates, which were even proved to be more susceptible to transformation into LCSCs than hepatocytes. (30) Furthermore, a recent study provided direct evidence that damage-induced reactivation of liver stem cells markedly increased cancer risk. (8) In vivo lineage tracing of specific cell types is rational for determining the cell origin of tumors but is presently only available in mice. However, our mouse models of DENinduced or inflammation-elicited hepatocarcinogenesis did not present typical cirrhosis like patients, and the LPC expansion was limited. Thus, the contribution of LPCs to liver cancer development would be underestimated using these mouse models. In the present study, a DEN-induced rat hepatocarcinogenesis model was used. This model presents progressive liver damage, inflammation, fibrosis and cirrhosis, and liver cancer, mimicking the pathogenesis of human liver cancer. We observed the expansion of LPCs during the cirrhosis stage of rat hepatocarcinogenesis, which is very similar to that in livers of patients with cirrhosis. Here, we provided direct evidence that expanded LPCs in a chronic inflammatory microenvironment were capable of initiating liver cancer in vivo. Depletion of Kupffer cells dramatically suppressed OV6 1 tumor development, which could be due to, at least partially, the reduction of LPC-derived LCSCs upon Kupffer cell depletion. These data suggested a positive role of Kupffer cells in LPC-originated LCSC generation upon chronic inflammation. Nevertheless, it should be noted that the model of DEN-induced rat liver cancer development could possess certain mechanistic discrepancies compared with human hepatocarcinogenesis. Indeed, the major risk factors of human liver cancer, including hepatitis virus infection, alcoholic liver disease, and nonalcoholic fatty liver disease, account for the vast majority of liver cancer worldwide. Chronic liver inflammation caused by these factors has been reported to facilitate liver cancer development. Hepatocellular carcinoma (HCC) can also occur in those hepatitis B or C virus carriers without chronic liver inflammation, indicating a direct oncogenic mechanism of viral infection. However, the presence of chronic inflammation remains a predominant risk factor for liver cancer development.
Inflammation facilitates tumorigenesis by providing a unique niche in favor of cellular transformation and expansion. Studies have indicated that TNF-a and IL-6 secreted by macrophages are the major mediators of the inflammatory process in liver. (32, 33) Naugler et al. proposed that IL-6 plays a pivotal role in HCC development and that gender-based IL-6 production accounts for the high HCC load in men. (11) Pikarsky reported that chronic hepatitis promoted hepatocyte transformation through TNF-a-induced nuclear factor-jB activation in an Mdr2 2/-liver inflammation model. (10) However, the influence of IL-6 or TNF-a on LPC transformation is largely unknown. Herein, we found that long-term exposure of TNF-a, but not IL-6, conferred LCSC traits to LPCs, suggesting the significance of TNF-a in LPC transformation during hepatocarcinogenesis. The extremely low expression of IL-6 receptor b (gp130) in LPCs may partially explain the nontumorigenicity of LPCs with long-term exposure to IL-6. TNF-a is a pleiotropic proinflammatory cytokine that plays important yet diverse roles in cell survival, differentiation, proliferation, and death. TNF-a is considered a carcinogen that causes cytogenetic changes including reactive oxygen species-elicited DNA damage and dysregulated mitosisrendered CIN. (20, 21) In this study, we found that longterm TNF-a exposure triggered the aberrant expression of UBD and Chk2, key mediators in mitosis, in LPCs and caused significant CIN. Nevertheless, expression of the DNA damage indicator c-H2AX was marginally altered, which excluded the possibility that the observed cytogenetic alteration was due to DNA damage.
The enhanced self-renewal capacity of stem/progenitor cells could be an early event contributing to tumor initiation. (34) Our lab and others have reported that the enhanced self-renewal of LPCs upon TGF-b exposure or stemness gene overexpression facilitated liver cancer development. (35) The hyperactivation of stemness regulators such as Oct4, Nanog, and Lin28 was demonstrated to promote hepatocarcinogenesis by augmenting self-renewal. (36, 37) In the current study, long-term TNF-a exposure increased the expression of Nanog and Lin28 and enhanced the self-renewal ability of LPCs. STAT3 has been implicated in the self-renewal of cancer stem cells. (38, 39) Here, our data indicated that activated STAT3 in TNF-a-stimulated LPCs was required for the up-regulation of Nanog and Lin28 and the enhanced self-renewal of LPCs. Furthermore, our data revealed that Src is required in TNF-a-induced STAT3 activation, which is consistent with a previous study indicating that TNFR1 could bind and activate Src kinase. (40) Moreover, S3I-201 or dasatinib treatment suppressed the up-regulation of Nanog and Lin28 in TNF-a-transformed LPCs and significantly inhibited their self-renewal ability. Therefore, the therapeutic effect of STAT3 or Src inhibitor in LPC-derived liver cancer is worthy of further investigation.
CK19 has been well established as a biliary lineage/ LPC marker in liver by numerous studies. It is routinely examined in our hospital, and its levels correlate with the prognosis of patients. (41) (42) (43) Nonetheless, the cell of origin of CK19 1 tumor is unclear to date, and the pathological classification of CK19 1 patients needs further stratification. Herein we found that the classic LPC marker OV6 was expressed in approximately 65% of CK19
1 HCCs and rarely detected in CK19 2 tumors. We thereby speculate that CK19 1 OV6 1 HCCs might, at least partially, derive from LPCs. Our data further demonstrated that CK19
1
OV6
1 patients presented a shorter time to recurrence and a shorter overall survival time than their counterpart. These findings suggested that CK19 and OV6 may serve as novel combinational biomarkers in the molecular classification of liver cancer, which could be useful in the prognosis prediction and individualized therapy. The existence of LCSCs is considered to be the origin of conventional chemoresistance. It is thereby important to decipher the different origin and distinct regulatory mechanism of LCSCs so as to develop novel therapeutic strategy. In the present study, we observed aberrant activation of STAT3 in WB-TNF or LEPC-TNF cells. Considering sorafenib was known to suppress STAT3 activation, (28, 29) we explored the sensitivity of WB-TNF or LEPC-TNF cells upon sorafenib exposure. As expected, sorafenib treatment not only abrogated STAT3 activation and the self-renewal ability of WB-TNF and LEPC-TNF cells but also triggered notable cell apoptosis, suggesting that LPC-derived liver cancer could be sensitive to sorafenib treatment. Consistently, our clinical data demonstrated that the overall therapeutic effect of sorafenib for liver cancer was disappointing, but CK19
1
OV6
1 patients could obviously benefit from sorafenib administration. These data suggest that LPC-derived liver cancer, at least in part, might be sensitive to sorafenib therapy, which is worthy of further investigation.
